Lexicon to Test Compounds with Nuevolution's Chematics

Jun 10, 2008

NEW YORK (GenomeWeb News) – Lexicon Pharmaceuticals said today it will use Nuevolution’s technology to identify small molecule lead compounds against a range of highly validated drug targets.

Under the agreement, Lexicon will pay Nuevolution an upfront payment and would also pay milestone payments and royalties on compounds that are identified using the Nuevolution Chemetics technology if candidate molecules advance through preclinical and clinical development and onto the market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Skipped Steps

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

Just a Few Bats

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

This Week in Nature

In Nature this week: investigation into the genetics of medulloblastoma, and more.

Genomics for the Trees

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.

Main menu